Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

doi:10.1371/journal.pone.0148924

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

PloS one - 1 Jan 2016

López-Cortés Luis F, Castaño Manuel A, López-Ruz Miguel A, Rios-Villegas María J, Hernández-Quero José, Merino Dolores, Jiménez-Aguilar Patricia, Marquez-Solero Manuel, Terrón-Pernía Alberto, Tellez-Pérez Francisco, Viciana Pompeyo, Orihuela-Cañadas Francisco, Palacios-Baena Zaira, Vinuesa-Garcia David, Fajardo-Pico Jose M, Romero-Palacios Alberto, Ojeda-Burgos Guillermo, Pasquau-Liaño Juan

Abstract excerpt

BACKGROUND AND OBJECTIVE: Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced previous virological failure (VF) while on protease inhibitor (PI) -based regimens. We have evaluated the effectiveness of two mtPI/rtv regimens in an actual clinical practice setting,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV-1

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Kaplan-Meier Estimate

Share to Ritonavir

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26872331
DOI: 10.1371/journal.pone.0148924
PMCID: PMC4752289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.PMID 26872331Read ↗

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.Semantic proximity Read ↗

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority studySemantic proximity Read ↗

Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.Semantic proximity Read ↗

Class-sparing regimens for initial treatment of HIV-1 infection.Semantic proximity Read ↗

[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].Semantic proximity Read ↗

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.Semantic proximity Read ↗

Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.Semantic proximity Read ↗

A virological benefit from an induction/maintenance strategy: the Forte trial.Semantic proximity Read ↗

Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.Semantic proximity Read ↗

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisSemantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.